SCHEMBL2315591

SCHEMBL2315591

CCOC(=O)c1cc2cc(Cl)cc(Cl)c2[nH]c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
MAOB P27338 1/20 0.49
GAA P10253 2/20 0.48
NPC1 O15118 1/20 0.48
POLB P06746 1/20 0.48
BAZ2B Q9UIF8 1/20 0.44
BAZ2A Q9UIF9 1/20 0.44
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 3/20 0.43
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
MEN1 O00255 2/20 0.42
GLA P06280 1/20 0.42
ATM Q13315 1/20 0.42
ALOX15 P16050 1/20 0.42
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2306202 0.89 ALDH1A1 (0.55) ALDH1A1L3MBTL1LMNAMAPTMAOB
SCHEMBL17603509 0.86 ALDH1A1 (0.51) ALDH1A1L3MBTL1LMNAMAPTMAOB
SCHEMBL4396474 0.82 ALOX15 (0.58) ALDH1A1L3MBTL1LMNAMAPTGAA
SCHEMBL30457751 0.82 ALOX15 (0.58) ALDH1A1L3MBTL1LMNAMAPTGAA
SCHEMBL1368975 0.79 HSD17B10 (0.49) ALDH1A1MAPTGAAPOLBKMT2A
SCHEMBL2312725 0.78 ALDH1A1 (0.55) ALDH1A1L3MBTL1LMNAMAPTGAA
SCHEMBL31345632 0.78 ALDH1A1 (0.57) ALDH1A1L3MBTL1LMNAMAPTGAA
SCHEMBL2309931 0.78 ALDH1A1 (0.57) ALDH1A1L3MBTL1LMNAMAPTGAA
SCHEMBL26617488 0.77 ALDH1A1 (0.56) ALDH1A1L3MBTL1LMNAMAPTGAA
SCHEMBL9705657 0.76 GLP1R (0.47) ALDH1A1L3MBTL1LMNAMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288549-B2 Glycine B antagonist MERZ PHARMA GMBH & CO. KGAA (DE) 2012-10-16 US disclosed
US-20110190342-A1 GLYCINE B ANTAGONIST HENRICH MARKUS 2011-08-04 US disclosed
EP-2350014-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2011-08-03 EP disclosed
WO-2010037533-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA (DE) 2010-04-08 WO disclosed
US-20070149520-A1 HCV Inhibitors And Methods Of Using Them RIGEL PHARMACEUTICALS, INC. (US) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149520-A1 HCV Inhibitors And Methods Of Using Them HAVCR2, GLS2, EIF2AK2 ALDH1A1 874/4885L3MBTL1 2227/4885LMNA 3994/4885
US-20110190342-A1 GLYCINE B ANTAGONIST GRIN2B, GLRB, GRIN2A ALDH1A1 4071/4885L3MBTL1 1155/4885LMNA 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.